Syngene International Limited has announced a scheduled analyst/investor meeting with Alquity Investment Management, set to take place on March 18, 2026. The announcement was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Meeting Details

The biotechnology services company has provided comprehensive details about the upcoming investor engagement:

Regulatory Compliance

Syngene International has emphasized its commitment to regulatory compliance by explicitly stating that no Unpublished Price Sensitive Information (UPSI) will be disclosed during the analyst/investor meeting. This declaration ensures adherence to SEBI guidelines regarding information sharing with institutional investors and analysts.

The company has also confirmed that details of this meeting will be made available on its official website at www.syngeneintl.com , maintaining transparency with all stakeholders.

Corporate Communication

The formal intimation was signed by Chethan Yogesh, Company Secretary & Compliance Officer, and was digitally executed on March 13, 2026. The communication was addressed to both BSE Limited and National Stock Exchange of India Limited, ensuring proper disclosure to both major stock exchanges where the company's shares are listed.

This scheduled meeting represents part of Syngene International's ongoing investor relations activities, providing institutional investors with opportunities for direct engagement while maintaining strict compliance with regulatory requirements.

Syngene International has reported export revenues of $6.6 million for February, marking a notable decline across both year-on-year and month-on-month comparisons. The pharmaceutical services company's latest export figures reflect challenging market conditions during the reported period.

Export Performance Analysis

The company's February export performance showed significant contractions across multiple timeframes. The data reveals both short-term and longer-term pressures on the company's international business operations.

Market Impact

The 22% year-on-year decline indicates sustained pressure on the company's export business compared to the same period in the previous year. Additionally, the 32% month-on-month decrease from January suggests intensifying challenges in the company's international operations during the recent period.

These export figures represent a key performance indicator for Syngene International's international business segment, reflecting the company's ability to serve global pharmaceutical and biotechnology clients. The dual decline across both comparative periods highlights the current operational environment facing the pharmaceutical services sector.